Phase Ib PAVO Study: Subcutaneous Daratumumab in Relapsed/Refractory Multiple Myeloma

Ian W. Flinn, MD, PhD; Shaji Kumar, MD; and Farhad Ravandi, MD, discuss important presentations in hematologic malignancies from the virtual ASCO 2020 as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji Kumar, MD Farhad Ravandi, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: September 23, 2020 Expired: September 22, 2021

Commentary by Jesús F. San-Miguel, MD, PhD, on treating patients with myeloma who experience biochemical relapse from Clinical Care Options (CCO)

Jesús F. San-Miguel, MD, PhD Released: September 22, 2020

Downloadable clinical resource from CCO includes a proposed 2020 treatment algorithm for myeloma

Shaji Kumar, MD Released: September 22, 2020

In this slideset from Clinical Care Options, Sarah A. Holstein, MD, PhD and Jonathan L. Kaufman, MD highlight key data for management of myeloma for veterans

Sarah A. Holstein, MD, PhD Jonathan L. Kaufman, MD Released: September 22, 2020